Vandenberghe Peter, Wlodarska Iwona, Tousseyn Thomas, Dehaspe Luc, Dierickx Daan, Verheecke Magali, Uyttebroeck Anne, Bechter Oliver, Delforge Michel, Vandecaveye Vincent, Brison Nathalie, Verhoef Gregor E G, Legius Eric, Amant Frederic, Vermeesch Joris R
Department of Human Genetics, Center for Human Genetics, KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium; Department of Haematology, KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium.
Department of Human Genetics, Center for Human Genetics, KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium.
Lancet Haematol. 2015 Feb;2(2):e55-65. doi: 10.1016/S2352-3026(14)00039-8. Epub 2015 Jan 20.
Hodgkin's lymphoma is one of the most common lymphoid neoplasms in young adults, but the low abundance of neoplastic Hodgkin/Reed-Sternberg cells in the tumour hampers the elucidation of its pathogenesis, biology, and diversity. After an incidental observation that genomic aberrations known to occur in Hodgkin's lymphoma were detectable in circulating cell-free DNA, this study was undertaken to investigate whether circulating cell-free DNA can be informative about genomic imbalances in Hodgkin's lymphoma.
We applied massive parallel sequencing to circulating cell-free DNA in a prospective study of patients with biopsy proven nodular sclerosis Hodgkin's lymphoma. Genomic imbalances in Hodgkin/Reed-Sternberg cells were investigated by fluorescence in-situ hybridisation (FISH) on tumour specimens.
By non-invasive prenatal testing, we observed several genomic imbalances in circulating cell-free DNA of a pregnant woman, who was subsequently diagnosed with early-stage nodular sclerosis Hodgkin's lymphoma stage IIA during gestation. FISH on tumour tissue confirmed corresponding genomic imbalances in Hodgkin/Reed-Sternberg cells. We prospectively studied circulating cell-free DNA of nine nodular sclerosis Hodgkin's lymphoma cases: eight at first diagnosis and one at first relapse. Seven patients had stage IIA disease and two had stage IVB disease. In eight, genomic imbalances were detected, including, among others, gain of chromosomes 2p and 9p, known to occur in Hodgkin's lymphoma. These gains and losses in circulating cell-free DNA were extensively validated by FISH on Hodgkin/Reed-Sternberg cells in biopsy samples. Initiation of chemotherapy induced normalisation of circulating cell-free DNA profiles within 2-6 weeks. The cell cycle indicator Ki67 and cleaved caspase-3 were detected in Hodgkin/Reed-Sternberg cells by immunohistochemistry, suggesting high turnover of Hodgkin/Reed-Sternberg cells.
In early and advanced stage nodular sclerosis Hodgkin's lymphoma, genomic imbalances in Hodgkin/Reed-Sternberg cells can be identified by massive parallel sequencing of circulating cell-free DNA at diagnosis. The rapid normalisation of circulating cell-free DNA profiles on therapy initiation suggests a potential role for circulating cell-free DNA profiling in early response monitoring. This finding creates several new possibilities for exploring the diversity of Hodgkin's lymphoma, and has potential implications for the future clinical development of biomarkers and precision therapy for this malignancy.
KU Leuven-University of Leuven and University Hospitals Leuven.
霍奇金淋巴瘤是年轻成年人中最常见的淋巴样肿瘤之一,但肿瘤中肿瘤性霍奇金/里德-斯腾伯格细胞数量稀少,阻碍了对其发病机制、生物学特性及异质性的阐明。在偶然观察到已知在霍奇金淋巴瘤中发生的基因组畸变可在循环游离DNA中检测到后,开展了本研究,以调查循环游离DNA是否能提供有关霍奇金淋巴瘤基因组失衡的信息。
在一项对经活检证实为结节硬化型霍奇金淋巴瘤患者的前瞻性研究中,我们对循环游离DNA应用了大规模平行测序。通过对肿瘤标本进行荧光原位杂交(FISH)研究霍奇金/里德-斯腾伯格细胞中的基因组失衡情况。
通过无创产前检测,我们在一名孕妇的循环游离DNA中观察到了几种基因组失衡情况,该孕妇随后在妊娠期被诊断为早期结节硬化型霍奇金淋巴瘤IIA期。对肿瘤组织进行的FISH证实了霍奇金/里德-斯腾伯格细胞中相应的基因组失衡。我们前瞻性地研究了9例结节硬化型霍奇金淋巴瘤患者的循环游离DNA:8例为初诊时,1例为首次复发时。7例患者为IIA期疾病,2例为IVB期疾病。在8例患者中检测到了基因组失衡,包括已知在霍奇金淋巴瘤中出现的2号染色体和9号染色体的增益等。循环游离DNA中的这些增减情况通过对活检样本中霍奇金/里德-斯腾伯格细胞进行的FISH得到了广泛验证。化疗开始后2 - 6周内,循环游离DNA谱恢复正常。通过免疫组化在霍奇金/里德-斯腾伯格细胞中检测到细胞周期指标Ki67和裂解的半胱天冬酶-3,提示霍奇金/里德-斯腾伯格细胞的高周转率。
在早期和晚期结节硬化型霍奇金淋巴瘤中,诊断时通过对循环游离DNA进行大规模平行测序可识别霍奇金/里德-斯腾伯格细胞中的基因组失衡。治疗开始后循环游离DNA谱迅速恢复正常,提示循环游离DNA谱在早期反应监测中具有潜在作用。这一发现为探索霍奇金淋巴瘤的异质性创造了多种新的可能性,并对该恶性肿瘤生物标志物的未来临床开发和精准治疗具有潜在意义。
鲁汶大学和鲁汶大学医院。